Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases - Top-Institutions - MDSpire

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

  • By

  • Jiwon Kim

  • Han Gyeol Kim

  • Seung Hyeun Lee

  • May 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Universidad de Alcalá
    Universidad de Alcalá

    Alcalá de Henares, Madrid

    Key Differentiators

    • Oncology

  • #3

    Aix Marseille University
    Aix Marseille University

    Marseille, Provence-Alpes-Côte d'Azur

    Key Differentiators

    • Oncology

  • #4

    INSERM
    INSERM

    Paris, Île-de-France

    Key Differentiators

    • Oncology

  • #5

    Hôpital de La Timone
    Hôpital de La Timone

    Marseille, Provence-Alpes-Côte d'Azur

    Key Differentiators

    • Oncology

Original Source(s)

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

  • by Jiwon Kim, Han Gyeol Kim, Seung Hyeun Lee

  • May 26, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential